Tonix Pharmaceuticals Holding (TNXP) Non Operating Interest Expenses (2011 - 2024)
Tonix Pharmaceuticals Holding (TNXP) posted Non Operating Interest Expenses of $280000.0 for Q4 2024, down 6.98% on a QoQ basis from $301000.0 in Q3 2024.
Powered by 
Analysis
Tonix Pharmaceuticals Holding (TNXP) Non Operating Interest Expenses (2011 - 2024) Analysis & Trends
Tonix Pharmaceuticals Holding has reported Non Operating Interest Expenses for 3 years, with the latest figure at $280000.0 in Q4 2024.
- On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $280000.0 in Q4 2024; TTM through Dec 2025 was $1.5 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $89000.0, down 92.79% from the prior year.
- Non Operating Interest Expenses was $280000.0 for Q4 2024 at Tonix Pharmaceuticals Holding, down from $301000.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $301000.0 in Q3 2024, with the low at $280000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 23.78 Mn |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 39.74 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 582,000.00 |
| 10 | Tonix Pharmaceuticals Holding | 220.65 Mn | 220.65 Mn | 12.84 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 280,000.00 |
| Sep 30, 2024 | 301,000.00 |
| Mar 31, 2012 | 901,646.00 |
| Mar 31, 2011 | -22.00 |